Craft

Advanced
  • Home
  •  / Akari Therapeutics
Akari Therapeutics

Akari Therapeutics

Stock Price

$2.5

2024-10-29

Market Capitalization

$30.4 M

2024-10-29

Akari Therapeutics Summary

Company Summary

Overview
Akari Therapeutics is a clinical-stage biopharmaceutical company. It develops inhibitors of acute and chronic autoimmune and inflammatory diseases, specifically the complement system, the eicosanoid or leukotriene system, and the bioamine system.
Type
Public
Status
Active
Founded
2014
HQ
New York, NY, US | view all locations
Website
https://www.akaritx.com/
Cybersecurity rating
Sectors

Table of Contents

Key People

  • Ray Prudo, Executive Chairman

    • Wynne Weston-Davies, Medical Director

      • Torsten Hombeck, Chief Financial Officer

        • Miles Nunn, Chief Scientific Officer

          LocationsView all

          3 locations detected

          • New York, NY HQ

            United States

            24 W 40th St

          • New York, NY

            United States

            135 W 41st St 5th floor

          • London, England

            United Kingdom

            Wimpole St, Marylebone

          Akari Therapeutics Financials

          Summary Financials

          Net income (Q1, 2026)
          ($14.5M)
          Cash (Q1, 2026)
          $2.8M
          EBIT (Q1, 2026)
          ($15.8M)
          Enterprise value
          $27.6M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX